Navigation Links
Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA)
Date:3/8/2011

is available in 50-unit and 100-unit vials, which Merz believes may allow for more precise billing and reduce wastage.

IMPORTANT SAFETY INFORMATIONWARNING: Distant Spread of Toxin EffectPostmarketing reports indicate that the effects of XEOMIN and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and at lower doses.CONTRAINDICATIONSXEOMIN is contraindicated in patients with a known hypersensitivity to the active substance botulinum toxin type A or to any of the components in the formulation and in the presence of infection at the proposed injection site(s).

WARNINGS AND PRECAUTIONS

  • The potency units of XEOMIN are not interchangeable with other preparations of botulinum toxin products.  Therefore, units of biological activity of XEOMIN cannot be compared to or converted into units of any other botulinum toxin products.
  • Hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea). If serious and/or immediate hypersensitivity reactions occur further injection of
    '/>"/>

  • SOURCE Merz Pharmaceuticals
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
    10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
    11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/21/2014)... , Aug. 21, 2014  Vermillion, Inc. (NASDAQ: ... gynecologic cancers and women,s health, has appointed Holly ... Managed Markets. Ms. Bauzon has a proven ... payer coverage for laboratory services companies. She has more ... PerkinElmer, Inc., where she held the position of Director, ...
    (Date:8/21/2014)... 21, 2014  Publicis Groupe customer engagement agency ... Partner and Healthcare Industry Group Leader, has been featured ... the most inspiring people in the life-sciences industry. Those ... and development, marketing, technology, creativity, strategy and medicine. ... a partner in its leading Rosetta Consulting practice. In ...
    (Date:8/21/2014)... 2014 /PRNewswire-iReach/ -- Inc. magazine today ... third straight year, No. 349 in Health on ... of the nation,s fastest-growing private companies. The list ... important segment of the economy—America,s independent entrepreneurs. Companies ... LinkedIn, Zillow, and many other well-known names gained ...
    Breaking Medicine Technology:Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2Shannon Hartley Shines in PharmaVOICE 100 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3
    ... 17, 2010 The oncology therapeutic area continues to ... the bio-pharmaceutical sector. It,s in this competitive environment that ... and tactics to support market education. To ... that companies inform thought leaders, physicians, patients and payers ...
    ... Tenn., Dec. 17, 2010 eTransX recently unveiled ... Messaging and Integration Engine), its application integration engine. ... it easy to integrate disparate healthcare information systems. ... performance improvements through 64-Bit computing and enhancements that ...
    Cached Medicine Technology:Research from Best Practices, LLC Delivers Effective Market Education Tactics and Strategies for New Oncology Products 2eTransX Unveils Latest Version of Its eTX HEMI 2
    (Date:8/21/2014)... 21, 2014 The City of Garden ... entertainment and programming for its inaugural “Re:Imagine Garden Grove ... 12, 2014, from 11 a.m. to 4 p.m., 2.85-miles ... cars and the downtown will be filled with diverse ... Community Arts Resources (CARS), for all to enjoy. , ...
    (Date:8/21/2014)... Aug. 21, 2014 (HealthDay News) -- Among seniors, dimming ... The study involved more than 2,500 people, aged 65 ... study and again two, six and eight years later. ... the person,s risk of death during the study period, the ... effect, researchers led by Sharon Christ of Purdue University in ...
    (Date:8/21/2014)... 21, 2014 A new study published ... increase in disability associated with speech problems from 2001-02 ... than 15% increase in disability associated with hearing problems. ... rising numbers of children who are experiencing communication disorders, ... , On a broader level, the new study, ...
    (Date:8/21/2014)... Aug. 21, 2014 Researchers in the United Kingdom ... can quickly and accurately diagnose a number of rare ... study published online today in Ophthalmology , ... Using a single test, doctors were able to tailor ... mutations reducing the time and money spent on diagnosis ...
    (Date:8/21/2014)... The report "Industrial Flue Gas Treatment Systems & ... Particulate Control, Mercury Control) by Application (Power Generation, ... Global Trends & Forecasts to 2019" defines and ... & services market with analysis and projection of ... The industrial flue gas treatment systems & services ...
    Breaking Medicine News(10 mins):Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 3Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 4Health News:Failing Vision Tied to Shorter Lifespans for Seniors 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 3Health News:New DNA test for diagnosing diseases linked to childhood blindness 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 4
    ... have felt elated using the tanning beds and cannot seem ... the elation than just the look good factor of the ... , have researched the background of the ‘feel good’ ... tan could also be igniting euphoric sensations, akin to the ...
    ... Jerry Mendell a neurologist, co-director of the Muscular ... professor of pediatrics, neurology and pathology at Ohio ... the Neuromuscular Research Program and Gene Therapy Center ... injection of Asklepios Biopharmaceutical Inc (AskBio’s) Biostrophin, which ...
    ... 570,000 children under the age of 15 die of AIDS ... - states a new global report highlighting concerns about the ... the World Health Organization (WHO) and the Joint United Nations ... HIV ART in low- and middle- income countries more than ...
    ... Rayburn, a cardiologist from the University of Alabama, Birmingham, told ... the drug showed no significant difference in the rate of ... or placebos. The drug Vioxx is produced and marketed by ... told a jury that the studies, covering a total of ...
    ... At fairing well in examining the heart and making ... They fair better than medical students, residents, and other ... in accurately identifying abnormal heart sounds. This was revealed ... Archives of Internal Medicine. ,The study was performed ...
    ... A new study has found that smoking and drinking at ... has exposed the adverse effects of tobacco and alcohol has ... second leading cause of cancer deaths, and doctors generally recommend ... Typically, the disease is diagnosed in people in their late ...
    Cached Medicine News:Health News:Wider Addictive Choices – Now, Tanned Addicts 2Health News:Trial Of DMD Gene Therapy Initiated At Ohio 2Health News:AIDS Deaths On The Rise Due To Low Access To Antiretroviral Treatment 2Health News:Could Long Tern Vioxx Users Suffer From Heart Attacks? 2